|
|
|
Insider
Information: |
Stelzer Laurie |
Relationship: |
Chief Financial Officer |
City: |
San Diego |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
3 |
|
Direct
Shares |
218,479 |
|
Indirect Shares
|
10,000 |
|
|
Direct
Value |
$10,885,890 |
|
|
Indirect Value
|
$420,100 |
|
|
Total
Shares |
228,479 |
|
|
Total
Value |
$11,305,990 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
1
|
Stock
price went up :
|
0
|
1
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
1.0
|
Percentage
Gain/Loss : |
0.0%
|
53.4%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Halozyme Therapeutics Inc |
HALO |
SVP, Chief Financial O... |
2020-02-22 |
116,167 |
2020-02-22 |
10,000 |
Premium* |
|
Arena Pharmaceuticals Inc |
ARNA |
EVP & Chief Financial ... |
2022-03-11 |
0 |
2021-03-01 |
0 |
Premium* |
|
Mirati Therapeutics, Inc. |
MRTX |
Chief Financial Officer |
2023-08-09 |
102,312 |
2022-06-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
37 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 2
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ARNA |
Arena Pharmaceuticals Inc |
EVP & Chief Financial Officer |
|
2022-03-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(37,208) |
0 |
0 |
- |
|
ARNA |
Arena Pharmaceuticals Inc |
EVP & Chief Financial Officer |
|
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,660 |
6,660 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
Chief Financial Officer |
|
2015-08-20 |
4 |
B |
$17.24 |
$172,384 |
I/I |
10,000 |
10,000 |
1.99 |
- |
|
ARNA |
Arena Pharmaceuticals Inc |
EVP & Chief Financial Officer |
|
2021-03-16 |
4 |
D |
$76.10 |
$331,492 |
D/D |
(4,356) |
14,904 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
|
2016-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,875 |
16,875 |
0 |
- |
|
ARNA |
Arena Pharmaceuticals Inc |
EVP & Chief Financial Officer |
|
2021-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,600 |
19,260 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
|
2017-02-03 |
4 |
D |
$12.26 |
$111,382 |
D/D |
(9,085) |
20,910 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
|
2017-06-15 |
4 |
D |
$13.05 |
$33,708 |
D/D |
(2,583) |
25,202 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
|
2017-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,875 |
27,785 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
|
2017-02-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,120 |
29,995 |
0 |
- |
|
ARNA |
Arena Pharmaceuticals Inc |
EVP & Chief Financial Officer |
|
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
21,462 |
36,366 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
|
2018-02-03 |
4 |
D |
$18.37 |
$151,828 |
D/D |
(8,265) |
40,057 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
|
2018-02-22 |
4 |
D |
$19.28 |
$75,944 |
D/D |
(3,939) |
47,510 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
|
2018-02-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,120 |
48,322 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
|
2018-06-15 |
4 |
D |
$19.02 |
$61,891 |
D/D |
(3,254) |
51,131 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
|
2018-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,392 |
51,449 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
|
2018-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,875 |
54,385 |
0 |
- |
|
MRTX |
Mirati Therapeutics, Inc. |
CFO |
|
2022-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
57,798 |
57,798 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
|
2019-02-03 |
4 |
D |
$16.12 |
$134,070 |
D/D |
(8,317) |
65,933 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
|
2019-02-14 |
4 |
D |
$16.54 |
$44,658 |
D/D |
(2,700) |
71,042 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
|
2019-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,809 |
73,742 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
|
2019-02-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,119 |
74,250 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
|
2019-02-22 |
4 |
D |
$16.81 |
$66,215 |
D/D |
(3,939) |
78,495 |
0 |
- |
|
MRTX |
Mirati Therapeutics, Inc. |
Chief Financial Officer |
|
2023-06-02 |
4 |
S |
$37.06 |
$172,218 |
D/D |
(4,647) |
80,015 |
0 |
% |
|
HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
|
2019-06-15 |
4 |
D |
$15.73 |
$53,608 |
D/D |
(3,408) |
81,962 |
0 |
- |
|
37 Records found
|
|
Page 1 of 2 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|